Stem cell laws debated at international conference
For its part, the World Health Organization announced it would hold a meeting “in Geneva on Tuesday to discuss the need for a universal and effective policy of stem cell research that is based on proof.”
The Swiss Health Ministry released a statement saying the Swiss would soon introduce laws “prohibiting the use of human cells and organs, and, in some cases, destroying them in medical research, but would continue to allow for research related to treating diseases from birth to old age.”
The conference will bring together leaders of more than 80 countries in the field of stem cell research, including representatives from the European Union, which, with Canada, Britain, India, Israel, Brazil and China, is the biggest donor of funding to the Swiss program.
The world’s top three funders of stem cell research in 2013 — China, the United States and Japan — provided an estimated $150 million each to fund the projects at the time, which are aimed at developing therapies for diseases such as heart disease, diabetes and Parkinson’s disease.
China’s new research center, based in the northeastern city of Nanjing, aims to develop cell therapies with potential to treat diseases caused by human-induced mutations, such as inherited blindness, Parkinson’s disease and Alzheimer’s disease.
One of the most promising stem cell research projects focuses on treating spinal cord injuries, said Dr. Jianfeng Xiong, a University of우리카지노 Florida professor who helped lead the development of the treatment, but the United States was not one of the top four donors.
“I don’t know that the U.S. is the place where they get the most money,바카라사이트” said Mr. Xiong, who is also a director at Stanford University’s Center for Gene Therapy, which is working on the treatment.
As part of the European Parliament’s initiative, researchers are also launching research into regenerative medicine, which would involve replacing damaged parts of the body with healthy ones — a treatment that has a long history of success in the United States.
“What we are really talking about in the United States is an entire sector that was so expensive,” said Dr. David Gartside of the Stanford Institute for Regenerative Medicine, who led a review team in Germany that reviewed the European research. “In Europe, they were getting $1 million for one stem cell.”
Some donors to the European Commission’s work have also expressed concerns about the ethical risks involved in their stem cells research.
In the wake of the controversy surrounding th